RxDoctor Payments Data

Layne Lemaire

Family · Lafayette, LANPI 1235554791

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 631 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 48 manufacturers reported payments, led by Amgen at 25.5% of the total. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,908in general payments, 2019–2025

Across 631 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • UCB, Inc.$909
  • Johnson & Johnson$832
  • Novartis$660
  • Radius Health, Inc.$457
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$12,67798%
  • Education$2312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,908 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$81,501
Medicare patients
527
Services billed
4,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab75$532,444
RinvoqUpadacitinib65$406,374
Enbrel SureclickEtanercept26$190,911
Cosentyx Sensoready (2 Pens)Secukinumab14$112,841
Enbrel MiniEtanercept13$97,570
KevzaraSarilumab22$93,513
Xeljanz XrTofacitinib Citrate11$73,511
Hydroxychloroquine Sulfate406$13,551
Sulfasalazine271$5,692
Celecoxib142$3,266
MethotrexateMethotrexate Sodium160$2,811
Febuxostat44$2,628
Prednisone410$1,941
Leflunomide30$1,422
Mycophenolate Mofetil17$1,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,904$406,37465 claims
SanofiKevzara$330$93,51322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →